These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35958337)

  • 1. Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study.
    Zhao D; Xu L; Wu J; She Y; Su H; Hou L; E H; Zhang L; Grossi F; Subramanian MP; Kim AW; Zhu Y; Chen C
    Transl Lung Cancer Res; 2022 Jul; 11(7):1468-1478. PubMed ID: 35958337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
    Zhai H; Zhong W; Yang X; Wu YL
    Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials.
    Sun L; Guo YJ; Song J; Wang YR; Zhang SL; Huang LT; Zhao JZ; Jing W; Han CB; Ma JT
    Front Oncol; 2020; 10():586596. PubMed ID: 33511076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
    Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R
    Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance.
    Zhou J; Chu X; Zhao J; Xie M; Wu J; Yu X; Fang Y; Li Y; Li X; Su C
    Biol Proced Online; 2023 Jul; 25(1):21. PubMed ID: 37488517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of neoadjuvant
    Xiong Y; Bian D; Huang Z; Yu H; Huang J; Zhang P; He W; Liu H
    Front Oncol; 2023; 13():1034897. PubMed ID: 36776292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant immune checkpoint inhibitor treatment + chemotherapy (vs. chemotherapy alone) for locally advanced non‑small cell lung cancer: A retrospective cohort study.
    Yang Y; Liu Z
    Oncol Lett; 2023 Jul; 26(1):292. PubMed ID: 37274484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation.
    Cheng Y; Yang B; Ouyang W; Jie C; Zhang W; Chen G; Zhang J; Yu J; Xie C
    Front Oncol; 2022; 12():920047. PubMed ID: 36081560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoimmunotherapy confers survival advantage for patients undergoing sleeve lobectomy.
    Chen T; Wen J; He Y; Zhong Y; Deng J; Chen Q; She Y; Jiang L; Xie D; Zhao D; Chen C
    Eur J Cardiothorac Surg; 2024 Mar; 65(4):. PubMed ID: 38539042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC.
    Zhang B; Xiao Q; Xiao H; Wu J; Yang D; Tang J; Li X; Wu Z; Zhou Y; Wang W
    Front Oncol; 2022; 12():858189. PubMed ID: 35712494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study.
    Lv C; Ma Y; Feng Q; Lu F; Chi Y; Wu N; Fang J; Yang Y
    J Thorac Dis; 2020 Oct; 12(10):5324-5335. PubMed ID: 33209366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
    Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
    Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
    Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
    Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Immune Checkpoint Inhibitor Therapy in Advanced
    Wiest N; Majeed U; Seegobin K; Zhao Y; Lou Y; Manochakian R
    Front Oncol; 2021; 11():751209. PubMed ID: 34868953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
    Tian T; Yu M; Li J; Jiang M; Ma D; Tang S; Lin Z; Chen L; Gong Y; Zhu J; Zhou Q; Huang M; Lu Y
    Front Oncol; 2021; 11():739090. PubMed ID: 34888234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.
    Benjamin DJ; Chen S; Eldredge JB; Schokrpur S; Li D; Quan Z; Chan JW; Cummings AL; Daly ME; Goldman JW; Gubens MA; Harris JP; Onaitis MW; Zhu VW; Patel SP; Kelly K
    JTO Clin Res Rep; 2022 Dec; 3(12):100427. PubMed ID: 36426286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Chan DW; Choi HC; Lee VH
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.